Posts found in:
Brad L. Schoenfeld
KO Client Scientific Aviation Acquired by ChampionX
- KO Firm
- |
- July 12, 2021
Scientific Aviation, Inc., which provides aerial methane emissions testing, was acquired by ChampionX Corporation, a global leader in chemistry solutions and highly engineered equipment and technologies. KO Law Firm supported Scientific Aviation through the acquisition, led by partner John Gaddis, along with attorneys Melissa Mellen and Keenan Weatherford, and paralegal…
Rethinking Supply Chain Agreements and Other Commercial Contracts to Manage Pandemic-Driven Uncertainty
- Brad L. Schoenfeld
- |
- January 11, 2021
Force majeure, supply chain agreements, commercial contracts and remote customer service — these are just a few of the many areas businesses are rethinking due to the COVID-19 pandemic. For life science companies, these areas take on significant and often urgent meaning as they apply to the pharmaceutical production and…
New Year, New Vacation Policy? What Colorado Employers Need to Know
- Brad L. Schoenfeld
- |
- February 14, 2020
In a tight labor market, it’s often the benefits and perks that help employers compete for talent. One key benefit an employer must consider is vacation. Should vacation be offered, and if so, how much and how should it be structured? What’s the real value of vacation to employees and…
KO Client National Credit Care Secures Growth Capital Investment
- KO Firm
- |
- February 14, 2020
KO client National Credit Care, a leading provider of credit rehabilitation services, recently announced that it has secured a growth capital investment from Long Ridge Equity Partners and Fenway Summer. The investment will enable Colorado-based National Credit Care to continue to grow and enhance its nationwide, industry-leading product and service…
How Emerging Companies Can Negotiate Better Life Sciences Commercial Contracts
- Brad L. Schoenfeld
- |
- January 9, 2020
Most life sciences companies negotiate numerous commercial contracts each year and must rely on big industry players for essential testing, supply and manufacturing partnerships. But these relationships can feel very unbalanced because large vendors seem to have far more negotiating power than any emerging company. Less favorable terms can have…
Why Emerging Life Science And Pharma Companies Should Apply The CRO Model To Commercial Contracts
- Brad L. Schoenfeld
- |
- February 19, 2019
2019 is off to a fast start in the life science, pharmaceutical and medical device industries with unprecedented market growth. Life sciences, in particular, continue on an upward trend, accounting for nearly 15 percent of venture deal flow in 2018, more than 60 percent of which were deals of $50…